GlassScriptPhysician profile
Keisha Gordon-Primus
NPI 1093196537
$2,917.77
in general payments reported to CMS, 2019-2025
15 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,024 · 2024: $794 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $483.09 | 2023-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $449.21 | 2023-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $331.68 | 2024-2025 | |
| Gilead Sciences, INC. | $259.18 | 2025 | Livdelzi, Epclusa |
| Otsuka America Pharmaceutical, INC. | $244.68 | 2023-2024 | Nuedexta |
| Edwards Lifesciences Corporation | $153.53 | 2025 | |
| Shield Therapeutics INC | $125.00 | 2023 | Accrufer |
| Abbvie INC. | $125.00 | 2025 | |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $117.12 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $116.43 | 2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $106.37 | 2023 | |
| Genentech USA, INC. | $101.82 | 2023 | Evrysdi |
| Coloplast Corp | $93.80 | 2025 | |
| Glaxosmithkline, LLC. | $92.05 | 2024 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keisha Gordon-Primus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.